
Aarti Pharma Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- Xanthine segment capacity expanding from 5000 to 9000 MT, expected full operationalization by FY27 with phased ramp-up starting H2 FY26.
- Future focus shifting toward pharmaceutical Xanthine in regulated markets, targeting 20-25% capacity allocation to pharma segment to stabilize margins.
- CDMO/CMO business growth guidance revised lower from 25% to around 20% due to some project delays, but strong growth expected next year and beyond.
- API segment volumes expected to grow due to capacity debottlenecking and filling Atali intermediate facility in FY26.
- FY26 growth driven mainly by product mix, stable volumes, and CDMO/CMO; FY27 anticipated to deliver bulk of 15% CAGR target with new capacities.
- Long-term revenue potential from CDMO projects ranges $25-$50 million per molecule if commercialized successfully.
- Overall, cautious growth guidance aiming to achieve at least 15% EBITDA CAGR over next 3 years.
See what Aarti Pharma management said on margin guidance — free account, 30 seconds.
Fundraise plans
- No specific mention of any current or planned new fundraising through debt or equity in the transcript.
- The company is focusing on brownfield expansions, such as the Xanthine capacity increase and Atali greenfield project, funded through internal resources or existing plans.
- CAPEX guidance indicates planned capital expenditure of around INR 550-600 crores over FY25 and FY26, with no explicit discussion on raising fresh capital through equity or debt.
- The management appears focused on stabilizing and ramping up capacity before considering additional CAPEX or fundraising.
- No direct questions or answers related to new equity or debt issuance were addressed in the sessions on pages 6-16.
See what Aarti Pharma management said on order book — free account, 30 seconds.
Capex plans
Yes- Brownfield expansion at current Xanthine site to increase capacity from 5,000 to 9,000 tonnes; project completion expected by Q3 next fiscal year with full operationalization over subsequent 2-3 quarters.
- Expansion includes filing for USFDA DMF and EUGMP CEP regulatory approvals within current fiscal year, targeting pharmaceutical segment.
- Atali greenfield project for CDMO/CMO and intermediate manufacturing progressing well; commissioning expected by Q4 FY25; phase one will have 60 reactors (+450 KL capacity) with scope for annual incremental expansions.
- Additional brownfield expansions and debottlenecking planned at Tarapur API site to meet growing demand.
- Total planned CAPEX of ₹550-600 crores over current and next fiscal years:
- - ₹170 crores invested in H1 FY25
- - ₹250 crores planned in H2 FY25
- - ₹150 crores planned in H1 FY26
- No immediate new CAPEX planned for Xanthine beyond current expansion; strategy to stabilize capacity before additional investments.
Track Aarti Pharma — get its next earnings analysis in your feed
How does Aarti Pharma rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Aarti Pharma rank in Pharmaceuticals & Biotechnology?
Compare Aarti Pharma against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Aarti Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem